Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Chronic pain affects millions globally, with limited therapeutic options.
• Neuro-inflammation plays a critical role in the pathogenesis of various chronic pain conditions.
• Low-dose naltrexone (LDN) is an opioid antagonist with emerging applications.

Purpose of the Study:

• To review the current understanding of low-dose naltrexone's clinical utility in chronic pain management.
• To elucidate the mechanisms underlying LDN's efficacy in pain relief.

Main Methods:

• Review of pre-clinical studies and clinical trials.
• Analysis of research investigating LDN's impact on neuro-inflammation and glial cell activity.
• Comparison of low-dose naltrexone effects with higher doses used for addiction treatment.

Main Results:

• Low-dose naltrexone demonstrates potential in alleviating symptoms of fibromyalgia, inflammatory bowel diseases, and multiple sclerosis.
• The primary mechanism involves the modulation of neuro-inflammation, targeting glial cells and inflammatory mediators in the central nervous system.
• Observed effects at low doses are distinct from those at higher, FDA-approved doses for opioid and alcohol dependence.

Conclusions:

• Low-dose naltrexone exhibits significant promise as a treatment for chronic pain conditions.
• The unique mechanism of action at low doses warrants further rigorous clinical investigation.
• LDN may offer a novel therapeutic strategy for managing chronic pain by targeting neuro-inflammation.